Blinatumomab added to frontline chemotherapy
Interleaving an immunotherapy with standard chemotherapy cycles improves survival in adults and children with newly diagnosed ALL.
E1910 (adults, OS HR 0.41) and AALL1731 (children, DFS HR 0.39) both stopped early for benefit; blinatumomab is now standard in consolidation regardless of MRD.
AALL1731 brings immunotherapy into the front-line treatment of the commonest childhood cancer, in the group of children where most relapses were occurring despite good initial risk. Blinatumomab was approved for this use in 2024 and paediatric protocols worldwide are being amended. Whether it can allow less chemotherapy, and its effect on very low-risk children, are the next questions.
E1910 changed the standard of care for adult B-ALL: immunotherapy is now part of front-line consolidation even for patients with no detectable leukaemia, because MRD-negative by flow cytometry does not mean cured. It also demonstrated that a T-cell engager can improve overall survival in a curative setting. Chemotherapy-light or chemotherapy-free regimens built on blinatumomab and inotuzumab are the next step.
Pages like this
not linked directly; found by shared links- PersonRachel E. Rau
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, CD19.
- PersonMark R. Litzow
Shares ECOG-ACRIN E1910, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD19.
- TrialTOWER
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- TrialD-ALBA (GIMEMA LAL2116)
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia.
- TargetCD3
Shares COG AALL1731, ECOG-ACRIN E1910, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission.
- CompanyAmgen
Shares Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, Acute lymphoblastic leukaemia.
- TrialFELIX
Shares CD19, Acute lymphoblastic leukaemia.